Bronchial thermoplasty: implementing best practice in the era of cost containment

Journal of Asthma and Allergy » Volume 2017:10 Pages 225—230

Laren D Tan,1 Nicholas Kenyon,2 Ken Y Yoneda,2 Samuel Louie2

1Division of Pulmonary, Critical Care, Hyperbaric and Sleep Medicine, Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, USA

Abstract: Increasing dependence on advanced technologies in the 21st century has created a dilemma between the practice and business of medicine. From information technology to robotic surgery, new technologies have expanded treatment possibilities and have potentially improved patient outcomes and safety. Simultaneously, their escalating costs limit access for certain patients and health care facilities. Nevertheless, medical decisions should not simply be based on cost. Input from physicians and other health care specialists as well as adherence to best practice position statements, are vital to implementing truly cost-effective strategies in medicine. Bronchial thermoplasty (BT), a US Food and Drug Administration approved bronchoscopy procedure in difficult-to-control persistent asthma, is a prime example of a new technology facing cost and implementation challenges. We discuss the specific indications and contraindications for BT and review recent real-world experiences that can provide the foundation for building a comprehensive asthma program that provides BT for difficult-to-control asthma patients who fail national guideline treatment recommendations after an adequate clinical trial of one. We also offer insight into the barriers to implementing a successful BT program and strategies for overcoming them.

Keywords: asthma, severe asthma, severe refractory asthma, biologic resistant asthma, BT

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Minorities Exposed to Dirtier Air, U.S. Study Finds https://t.co/WQh1EwCw4n
1hreplyretweetfavorite
Interasma RT @Aller_MD: It's a Food #Allergy! Where's the School Nurse? https://t.co/zAAlrkRxw5
1hreplyretweetfavorite
Interasma RT @Aller_MD: FDA OKs Glaxo's inhaler, first one to combine three medicines https://t.co/KWhVMPYcy6
1hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergy, Asthma & Immunology! https://t.co/1NJpDoYxrM Thanks to @mnt_allergy @GoAllergy #respiratory #news
1hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergists on Social Media! https://t.co/prrVfRfHhR Thanks to @brendausa @AACMaven @Compassion4Ana #respiratory #n
1hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma